← Eichor
Study identifier: NCT03981497 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms

Condition: Liver Cancer · Liver Metastasis Colon Cancer · Kidney Cancer  ·  Sponsor: Francesco De Cobelli

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA. Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path

This description comes directly from the study's public registry record.

Talk to the study team

Francesco De Cobelli, MD  ·  +390226432529  ·  decobelli.francesco@hsr.it

Stephanie Steidler, PhD  ·  +3926432529  ·  steidler.stephanie@hsr.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Ospedale San RaffaeleMilan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03981497